Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

How to manage toxicities from Immune Checkpoint Inhibitors?

Patients treated with Immune checkpoint inhibitors like anti CTL-4 anti PD-1 anti PD-L1 drugs, may develop side effects. As every tissue is sensitive to developing side effects and it's very important to recognize these side effects early on because the earlier they are in the control and the better for the patients.

In this OncologyPRO educational video of the "How to" series, John Haanen explains how to manage immunotherapy induced colitis, hepatitis and pneumonitis.

References:

J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan, on behalf of the ESMO Guidelines Committee; Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up , Annals of Oncology, Volume 28, Issue suppl_4, 1 July 2017, Pages iv119–iv142, https://doi.org/10.1093/annonc/mdx225

View and download the ESMO Guidelines Slide Set on Management of toxicities from immunotherapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings